leki inkretynowe w cukrzycy typu 2 (agoniści receptora GLP-1 vs inhibitory DPP-4): powikłania sercowo-naczyniowe, hipoglikemia

Zhang Z  i wsp. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017 Mar 1;16(1):31. (dostępny pełen tekst ang. )

Conclusions:
GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.

Cardiovascular Diabetology, marzec 2017

 

Dodaj komentarz